On the chart you can see the default numbers in dynamics for Pieris Pharmaceuticals, Inc. (PIRS). Companys revenue shows the average of 23.101 M which is 0.394 % gowth. The average gross profit for the whole period is 13.473 M which is 0.403 %. The average gross profit ratio is 0.751 %. The net income growth for the company last year performance is -0.215 % which equals -13.751 % % on average for the whole company history.,
Diving into the fiscal trajectory of Pieris Pharmaceuticals, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.595. In the realm of current assets, PIRS clocks in at 38.68 in the reporting currency. A significant portion of these assets, precisely 26.366, is held in cash and short-term investments. This segment shows a change of -0.554% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0 in the reporting currency. This figure signifies a year_over_year change of -1.000%. Shareholder value, as depicted by the total shareholder equity, is valued at 26.758 in the reporting currency. The year over year change in this aspect is -0.042%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 6.039, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.
The financial landscape of Pieris Pharmaceuticals, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.115. The company recently extended its share capital by issuing 19.8, marking a difference of 32.432 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to 12002000.000 in the reporting currency. This is a shift of -1.565 from the previous year. In the same period, the company recorded 1.78, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0.07, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Pieris Pharmaceuticals, Inc.'s revenue saw a change of 0.653% compared with the previous period. The gross profit of PIRS is reported to be 41.03. The company's operating expenses are 56.87, showing a change of -7.075% from the last year. The expenses for depreciation and amortization are 1.78, which is a -0.782% change from the last accounting period. Operating expenses are reported to be 56.87, which shows a -7.075% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.636% year-over-year growth. The operating income is -15.84, which shows a -0.636% change when compared to the previous year. The change in the net income is -0.215%. The net income for the last year was -24.54.
